Taken together, our data suggest that RNF4 and its downstream target genes, BMP6 and RGMb, are essential for the survival of osteosarcoma and RTKi-resistant melanoma cells and that RNF4 and BMP6 may serve as markers associated with poorer prognosis in sarcomas. This evidence concerns the gene BMP6 and sarcoma.